KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neogenomics (NEO) Receivables - Net (2016 - 2026)

Neogenomics filings provide 17 years of Receivables - Net readings, the most recent being $167.4 million for Q1 2026.

  • On a quarterly basis, Receivables - Net rose 10.72% to $167.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $167.4 million, a 10.72% increase, with the full-year FY2025 number at $159.2 million, up 5.78% from a year prior.
  • Receivables - Net hit $167.4 million in Q1 2026 for Neogenomics, up from $159.2 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $167.4 million in Q1 2026 to a low of $110.8 million in Q1 2022.
  • Median Receivables - Net over the past 5 years was $140.3 million (2024), compared with a mean of $137.5 million.
  • Biggest five-year swings in Receivables - Net: increased 18.43% in 2023 and later grew 2.55% in 2025.
  • Neogenomics' Receivables - Net stood at $119.7 million in 2022, then rose by 9.62% to $131.2 million in 2023, then rose by 14.72% to $150.5 million in 2024, then grew by 5.78% to $159.2 million in 2025, then grew by 5.14% to $167.4 million in 2026.
  • The last three reported values for Receivables - Net were $167.4 million (Q1 2026), $159.2 million (Q4 2025), and $155.3 million (Q3 2025) per Business Quant data.